Neural Analytics yesterday reported raising nearly $10 million for the robot-assisted brain ultrasound device it’s developing.
Los Angeles-based Neural Analytics’ NeuralBot is designed to work with its Lucid M1 transcranial doppler utrasound to provide non-invasive blood flow monitoring. In June the company won CE Mark approval in the European Union for NeuralBot.
In a funding round begun in May, Neural Analytics said it raised $9.5 million from 18 unnamed investors in an offering of debt, options, warrants and other securities, according to a Nov. 28 regulatory filing.
In January the company raised $15 million in a Series B round led by Alpha Edison.
“We are committed to advancing brain healthcare through transformative technology that empowers neurologists with the critical information needed to make clinical decisions and improve patient outcomes,” co-founder & CEO Leo Petrossian said in June. “Our products provide clinicians with a cost effective and non-invasive assessment of a patient’s brain health, and can help clinicians diagnose brain disorders, potentially without the need for more invasive testing.”
“This technology allows us to look inside the brain, evaluate blood flow characteristics and track emboli in patients. It provides us with critical information on brain health in real-time to help us diagnose neurological disorders, prior to the need for additional, more invasive testing,” added Dr. Claudio Baracchini of Italy’s University of Padua.
